Literature DB >> 4726231

Spironolactone as a nonspecific treatment for primary aldosteronism.

E L Bravo, H P Dustan, R C Tarazi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4726231     DOI： 10.1161/01.cir.48.3.491

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

Review 1.  Medical management of primary hyperaldosteronism.

Authors:  E L Bravo
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 2.  Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.

Authors:  Emmanuel L Bravo
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 3.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

Review 4.  Endocrine causes of secondary hypertension.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-07       Impact factor: 3.738

5.  Hormones other than aldosterone may contribute to hypertension in 3 different subtypes of primary aldosteronism.

Authors:  Fei Ye; Zheng-Yi Tang; Jing-Cheng Wu; Yang Yang; Xiu-Li Tian; Jia-Jia Huang; Shan-Shan Zhang; Guang Ning
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-02-27       Impact factor: 3.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.